Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

August 30, 2022

Study Completion Date

December 23, 2022

Conditions

DiabetesWound InfectionABSSSIHealthy Volunteers

Interventions

DRUG

Tebipenem Pivoxil Hydrobromide

Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses

Trial Locations (1)

Hartford Hospital, Hartford